A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.
暂无分享，去创建一个
T. Powles | S. Sundar | S. Brock | Robert J. Jones | S. Crabb | G. Faust | S. Hussain | J. Gale | O. Parikh | S. Hinsley | D. Enting | U. McGovern | E. Soulis | J. Barber | J. Frew | L. Dempsey | Avril Trevethan | Y. Song | G. Ratnayake | K. Lees